EGF Receptor and c-erbB-2 in Stomach Cancer
Author Information
Author(s): N.R. Lemoine, S. Jain, F. Silvestre, C. Lopes, C.M. Hughes, E. McLelland, W.J. Gullick, M. Isabel Filipe
Primary Institution: ICRF Molecular Oncology Group, MRC Cyclotron Building, Hammersmith Hospital
Hypothesis
The study aims to determine the frequency of EGF receptor and c-erbB-2 gene amplification and rearrangement in gastric cancer.
Conclusion
Abnormal expression of the EGF receptor and c-erbB-2 proto-oncogene occurs at a significant frequency in gastric cancer, regardless of gene amplification.
Supporting Evidence
- Overexpression of c-erbB-2 was detected in 26% of cases examined.
- EGF receptor overexpression was found in 18% of gastric cancers.
- Gene amplification of c-erbB-2 was observed in 13% of cases.
- EGF receptor gene amplification was rare, detected in only 2 cases.
- Immunohistochemical detection of c-erbB-2 was effective in paraffin sections.
Takeaway
This study looked at how often certain genes are overactive in stomach cancer, which can help doctors understand the disease better.
Methodology
The study involved examining gastrectomy specimens for gene amplification and expression levels using Southern blotting and immunohistochemistry.
Limitations
The study's sample size is relatively small, and the results may not be generalizable to all gastric cancer cases.
Want to read the original?
Access the complete publication on the publisher's website